Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
MYOKARDIA RG (NQ: MYOK)
48.45 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 8:00 PM EDT, Jun 22, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 48.45
Bid (Size) 41.40 (100)
Ask (Size) 49.50 (1000)
Prev. Close 48.45
Today's Range 48.45 - 48.45
52wk Range 12.60 - 62.83
Shares Outstanding 35,966,061
Dividend Yield N/A
Performance
YTD
+12.81%
+12.81%
1 Month
+1.57%
+1.57%
3 Month
-4.91%
-4.91%
6 Month
+12.54%
+12.54%
1 Year
+231.85%
+231.85%
Top News
More News
Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited — Research Highlights Gr
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Willis Towers Watson Public... Read More
from GlobeNewswire News Releases
MyoKardia Announces Pricing of Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of... Read More
from GlobeNewswire News Releases
More News
Read More
MyoKardia Announces Proposed Public Offering of Common Stock
from GlobeNewswire News Releases
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
from GlobeNewswire News Releases
MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
from GlobeNewswire News Releases
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
from GlobeNewswire News Releases
MyoKardia Reports First Quarter 2018 Financial Results
from GlobeNewswire News Releases
MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018
from GlobeNewswire News Releases
Free Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia, Nektar Therapeutics, and Novavax
from PR Newswire
New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial — Consolidated Revenues, Company Growth, and Expectations for 2
from GlobeNewswire News Releases
MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.